Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00104273 · ClinicalTrials.gov registry record · Phase 2
Rasagiline 1 mg and 2 mg Added to Aricept 10 mg Daily in Patients With Mild to Moderate Alzheimer's Disease (AD)
A Phase 2 study of Dementia and Alzheimers Disease, sponsored by Teva Branded Pharmaceutical Products R&D.
- Completed
- Registry status
- Phase 2
- Development phase
- 376
- Enrollment target
- 20
- Study locations
NCT00104273: Completed Phase 2 study of Dementia and Alzheimers Disease, sponsored by Teva Branded Pharmaceutical Products R&D.
NCT00104273 is a Phase 2 study of Dementia and Alzheimers Disease that has completed, run by Teva Branded Pharmaceutical Products R&D. The registered enrollment target is 376 participants, below the 7,721-participant average among 199 other Dementia trials with a reported enrollment target (95% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00104273, a Phase 2 study of Dementia and Alzheimers Disease, has completed, sponsored by Teva Branded Pharmaceutical Products R&D.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 376 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the safety, tolerability, and efficacy of two dose levels of rasagiline mesylate versus placebo in patients with mild-to-moderate Alzheimer's Disease who are taking Aricept.
Conditions Studied
Interventions
- DRUG Rasagiline
Study Locations (20)
California
- East Bay Region Associates in Neurology - Berkeley
- Margolin Brain Institute - Fresno
- Collaborative Neuroscience Network - Garden Grove
- San Francisco Clinical Research Center - San Francisco
- Neurological Research Institute - Santa Monica
Alabama
- Collaborative Neuroscience Network - Huntsville
- North Alabama Neuroscience Research - Huntsville
Florida
- Premiere Research Institute - West Palm Beach
- North Broward Medical Center/Memory Disorder Center - West Palm Beach
Georgia
- Emory University Wesley Woods Health Center - Altanta
- Dekalb Neurology Associates, LLC - Decatur
Arizona
- Northwest Neurospecialists, PLLC - Tucson
Arkansas
- Clinical Study Centers, LLC - Little Rock
Colorado
- University of Colorado Health Sciences Center - Denver
Illinois
- Radiant Research - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 376 participants |
| Start Date | 2004-08 |
| Phase | Phase 2 |
What the finished NCT00104273 record still lists
NCT00104273 is an interventional study that assigns participants to a tested intervention. The registered 376 participants enrollment target is mid-sized for trials with a published cap, below the 7,721-participant average among 199 other Dementia trials with a reported enrollment target (95% lower).
The record links to 2 conditions, with Dementia appearing as the primary indexed condition, and to 1 intervention - of which Rasagiline is the first listed.
NCT00104273 names 20 study sites across 13 states, led by California, Alabama, Florida.
Frequently Asked Questions
What is clinical trial NCT00104273 about?
NCT00104273 is a clinical study titled "Rasagiline 1 mg and 2 mg Added to Aricept 10 mg Daily in Patients With Mild to Moderate Alzheimer's Disease (AD)". The purpose of this study is to evaluate the safety, tolerability, and efficacy of two dose levels of rasagiline mesylate versus placebo in patients with mild-to-moderate Alzheimer's Disease who are taking Aricept.
What is the current status of trial NCT00104273?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 376 participants. The study started on 2004-08.
What conditions does trial NCT00104273 study?
This clinical trial studies the following conditions: Dementia, Alzheimers Disease.
What interventions are being tested in trial NCT00104273?
The interventions under investigation include: Rasagiline (DRUG).
Who is sponsoring clinical trial NCT00104273?
This trial is sponsored by Teva Branded Pharmaceutical Products R&D, which has 167 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00104273 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dementia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00104273's enrollment target sits among peer trials
376 59th of 199 higher than 141 of 199 other Dementia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Dementia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Clinical Trial Evaluating the Efficacy of AGB101 for Reducing Hippocampal Overactivity in Older Adults
RECRUITING · Phase 2
-
Assessment of Foralumab Safety and Modulation of Microglial Activation in Alzheimer's Disease
RECRUITING · Phase 2
-
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
RECRUITING · Phase 2
-
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
RECRUITING · Phase 2
-
Testing the Pain Clinical Practice Guideline
RECRUITING · Phase 2
-
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03102125 · 376 participants · Phase 4
Allograft Dysfunction in Heart Transplant
- NCT05055297 · 376 participants · NA
SELUTION4BTK Trial
- NCT05912647 · 376 participants · NA
Enhancing Diabetes Management Approaches for Patients With Uncontrolled Diabetes
- NCT05963971 · 376 participants · NA
A Bilingual Virtually-based Intervention (PEDALL) for the Prevention of Weight Gain in Childhood ALL Patients Considering Key Genetic and Sociodemographic Risk Factors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia